SingleTimeMicroneedles

STM’s mission is to improve animal/community health worldwide with a thermally-stable, multi-dose microneedle patch that lowers deployment costs and increases access to drugs and vaccines.

Development deal with a top 10 human/veterinarian pharma company that includes up-front non-dilutive funding, development money, as well as royalties.
Development deal with an mRNA manufacturer to become the first company to potentially bring mRNA vaccines to the animal health market.
We are in negotiations with two other $1B+ companies with similar deal structure.
We have signed also signed two contracts with start-up pharmaceutical companies that would, upon successful internal development, lead to a mixture of all three (CRO/CMO/Licensing) revenues.

Current painful, costly needle-injections require multiple booster shots and expensive cold-chain transport/storage. They also need specialized personnel for deployment and leave biohazard waste. Oral dosing comes with losses in efficacy and potential GI issues. These physical, organizational, biological, and personnel demands lead to drug/vaccine access inequality and hinder any effective domestic/global health improvement plan.
Results:
Non/under-vaccinated populations
Billions of losses in the animal industry
Lack of access to certain drugs
Slow en/pandemic response

STM’s core technology is an easily -administered painless patch applied on skin to embed arrays of microneedles (MNs). Minutes later, the patch is removed and MNs are imperceptibly embedded in superficial skin. The MNs are a biodegradable polymer, like those in sutures, and are engineered to release drugs/vaccines immediately, repeatedly, or over a period of time, in a single application. Patches are temp stable, avoiding any refrigeration and are being developed for animal and human health applications.

Development (CRO)
-Partner with pharmaceutical companies to test their product in our thermal stabilization and microneedle patch manufacturing process
-Support drug development to increase efficiency/effectiveness of biologic/therapeutic with our processes
Manufacturing (CMO)
-Partner with institutions to manufacture patches for research projects
-Partner with start-up through mid-sized pharmaceutical companies to test their products’ capabilities within different delivery systems
Royalties/Licensing
-Licensing rights to an internally developed STM product
-Pharmaceutical royalties

gener8tor gBeta Health (incubator)
Innovation Space Delaware (accelerator)
Gust-Peachtree Financial (accelerator)
University of Connecticut Technology Incubator Program (5yr residential program for lab, office, and services)